Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navepegritide - Ascendis Pharma

Next Previous
Drug Profile

Navepegritide - Ascendis Pharma

Alternative Names: ACP-015; C-type natriuretic peptide prodrug - Ascendis Pharma; Navepegritide; Navepegritide- Ascendis Pharma; TransCon C-type natriuretic peptide; TransCon CNP

Latest Information Update: 16 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascendis Pharma
  • Developer Ascendis Pharma; VISEN Pharmaceuticals
  • Class Natriuretic peptides
  • Mechanism of Action C-type natriuretic replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Achondroplasia
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Achondroplasia

Most Recent Events

  • 09 Jun 2025 Ascendis Pharma plans phase III trial in quarter four of 2025
  • 02 Jun 2025 FDA assigns PDUFA action date of (30/11/2025) for Navepegritide for Achondroplasia (In Children)
  • 02 Jun 2025 USFDA accepts NDA for Navepegritide for Achondroplasia (In Children) for priority review

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top